^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KITE-439

    i
    Other names: KITE-439, KITE 439, HPV16 E7 T cell receptor engineered T cells, E7 T-cell receptor (TCR) T cells
    Associations

    News

    Trials
    Company:
    Fosun Pharma, Gilead, National Institutes of Health
    Drug class:
    HPV-16 E7 protein inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
    P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Mar 2041 --> Dec 2040 | Trial primary completion date: Mar 2041 --> Dec 2040
    Trial completion date • Trial primary completion date
    |
    Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
    over1year
    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
    P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Nov 2026 --> Mar 2041 | Trial primary completion date: Nov 2026 --> Mar 2041
    Trial completion date • Trial primary completion date
    |
    Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718